论文部分内容阅读
目的比较利福喷丁和利福平临床治疗肺结核的安全性和效果。方法选取102例肺结核患者,随机分成利福喷丁组(RFT组)52例和利福平组(RFP组)50例,两组均治疗3个疗程,每个疗程2个月,治疗后评价两组的临床效果及药物安全性。结果治疗后进行痰检和X线胸部平片检测,两组痰检转阴数、病灶吸收数和空洞闭合数差异显著(P<0.05),RFT组总有效率为94.23%,显著高于RFP组的80.00%(P<0.05),且RFT组药物副作用小(P<0.01)。结论利福喷丁临床治疗肺结核比利福平效果好,药物副作用小,具较强的抗菌活性和稳定的血药浓度等优势,有利于临床应用推广。
Objective To compare the safety and efficacy of rifapentine and rifampin in the treatment of pulmonary tuberculosis. Methods A total of 102 patients with pulmonary tuberculosis were randomly divided into two groups: the rifampicin group (RFT group), 52 cases and the rifampin group (RFP group), 50 cases. Both groups were treated with 3 courses of 2 months for each course of treatment. After treatment, Clinical efficacy and drug safety in both groups. Results After sputum examination and X-ray plain film examination, there was significant difference between the two groups (P <0.05). The total effective rate was 94.23% in RFT group, which was significantly higher than that of RFP Group (80.00%, P <0.05), and side effects of RFT group were less (P <0.01). Conclusions Rifampicin is more effective than rifampicin in treating pulmonary tuberculosis, with less side effects, strong antibacterial activity and stable plasma concentration, which is good for clinical application.